Literature DB >> 6863539

Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.

M B Penno, E S Vesell.   

Abstract

To investigate mechanisms that control large variations among normal uninduced subjects in the elimination of the model compound antipyrine (AP) and other drugs, AP was administered to 144 subjects (83 unrelated adults and 61 members of 13 families). Thereafter, at regular intervals for 72 h, the urine of each subject was collected and concentrations of AP and its three main metabolites measured. From these urinary concentrations, rate constants for formation of each AP metabolite were calculated. Trimodal curves were observed when values for each AP rate constant were plotted in 83 unrelated subjects; probit plots of these values showed inflections at the two antimodes of each trimodal distribution. All members of our 13 families were assigned one of three phenotypes determined by where their AP metabolite rate constant placed them in the trimodal distributions derived from the 83 unrelated subjects. In each family, pedigree analysis to identify the mode of transmission of these three phenotypes was consistent with their monogenic control. These results provide evidence for a new polymorphism of drug oxidation in man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6863539      PMCID: PMC370374          DOI: 10.1172/jci110924

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Genetic control of dicumarol levels in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

2.  Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: the role of genetic factors.

Authors:  P B Andreasen; A Froland; L Skovsted; S A Andersen; M Hauge
Journal:  Acta Med Scand       Date:  1973-06

3.  Genetic and environmental influence on halothane metabolism in twins.

Authors:  H F Cascorbi; E S Vesell; D A Blake; M Helrich
Journal:  Clin Pharmacol Ther       Date:  1971 Jan-Feb       Impact factor: 6.875

4.  Genetic and environmental factors affecting ethanol metabolism in man.

Authors:  E S Vesell; J G Page; G T Passananti
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

5.  Genetic control of drug levels in man: antipyrine.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-07-05       Impact factor: 47.728

6.  Metabolism of drugs. LIX. A new metabolite of antipyrine.

Authors:  H Yoshimura; H Shimeno; H Tsukamoto
Journal:  Biochem Pharmacol       Date:  1968-08       Impact factor: 5.858

7.  Rapid gas-liquid chromatographic estimation of antipyrine in plasma.

Authors:  L F Prescott; K K Adjepon-Yamoah; E Roberts
Journal:  J Pharm Pharmacol       Date:  1973-03       Impact factor: 3.765

8.  Norphenazone, a new metabolite of phenazone in human urine.

Authors:  J D Baty; D A Evans
Journal:  J Pharm Pharmacol       Date:  1973-01       Impact factor: 3.765

9.  Genetic control of drug levels in man: phenylbutazone.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-03-29       Impact factor: 47.728

10.  Effect of age and sex on human drug metabolism.

Authors:  K O'Malley; J Crooks; E Duke; I H Stevenson
Journal:  Br Med J       Date:  1971-09-11
View more
  15 in total

Review 1.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

2.  Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots.

Authors:  P R Jackson; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

3.  Simplified approaches to the determination of antipyrine pharmacokinetic parameters.

Authors:  J M Scavone; D J Greenblatt; G T Blyden; J S Harmatz; P J Graziano
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

4.  Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine.

Authors:  G T Blyden; D J Greenblatt; B W LeDuc; J M Scavone
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

6.  Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.

Authors:  M W Teunissen; G J Bruining; B M De Jongh; E W Tenkate-Westerhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

Review 7.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

8.  Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine.

Authors:  B Gachályi; A Vas; K Csillag; B Nagy; F Kocsis; A Káldor
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism.

Authors:  Y Caraco; E Zylber-Katz; E M Berry; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.